Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 2/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.33 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.33 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.33 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14201644 | 0.90 | AQP1 (0.39) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL8225710 | 0.88 | AQP1 (0.45) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL8225938 | 0.87 | AQP1 (0.50) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL8225939 | 0.85 | CA2 (0.41) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL14201643 | 0.85 | AQP1 (0.42) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL5361392 | 0.84 | AQP1 (0.51) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL14201642 | 0.84 | AQP1 (0.42) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL8220740 | 0.84 | AQP1 (0.42) | AQP1CA2 | |
| SCHEMBL8225828 | 0.84 | AQP1 (0.51) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL5361397 | 0.84 | AQP1 (0.51) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2007-11-01 | — | — | US | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | AQP1 1697/4885PRKAB2 4344/4885PRKAG1 4363/4885 |
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | TBXA2R, HTR2C, NPY1R | AQP1 2199/4885PRKAB2 4525/4885PRKAG1 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.